These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 9154180)
21. American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the journey: the long and winding road of chemoprevention agent development. Meyskens FL Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2038-41. PubMed ID: 17119025 [No Abstract] [Full Text] [Related]
22. Strategy and planning for chemopreventive drug development: clinical development plans II. Kelloff GJ; Crowell JA; Hawk ET; Steele VE; Lubet RA; Boone CW; Covey JM; Doody LA; Omenn GS; Greenwald P; Hong WK; Parkinson DR; Bagheri D; Baxter GT; Blunden M; Doeltz MK; Eisenhauer KM; Johnson K; Knapp GG; Longfellow DG; Malone WF; Nayfield SG; Seifried HE; Swall LM; Sigman CC J Cell Biochem Suppl; 1996; 26():54-71. PubMed ID: 9154168 [TBL] [Abstract][Full Text] [Related]
23. The next phase of chemoprevention research. Cohen EE; Schilsky RL Cancer Prev Res (Phila); 2011 Mar; 4(3):293-5. PubMed ID: 21372026 [TBL] [Abstract][Full Text] [Related]
25. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396 [No Abstract] [Full Text] [Related]
26. Synergistic effects of (--)-epigallocatechin gallate with (--)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Suganuma M; Okabe S; Kai Y; Sueoka N; Sueoka E; Fujiki H Cancer Res; 1999 Jan; 59(1):44-7. PubMed ID: 9892181 [TBL] [Abstract][Full Text] [Related]
27. Lycopene in cancer prevention and treatment. Seren S; Lieberman R; Bayraktar UD; Heath E; Sahin K; Andic F; Kucuk O Am J Ther; 2008; 15(1):66-81. PubMed ID: 18223356 [TBL] [Abstract][Full Text] [Related]
28. Chemoprevention clinical trials: it is time to turn success into progress. Brown PH Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123 [No Abstract] [Full Text] [Related]
29. Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. Skopinski P; Szaflik J; Duda-Król B; Nartowska J; Sommer E; Chorostowska-Wynimko J; Demkow U; Skopinska-Rózewska E Int J Mol Med; 2004 Oct; 14(4):707-11. PubMed ID: 15375605 [TBL] [Abstract][Full Text] [Related]
30. Cancer prevention research: back to the future. Lippman SM Cancer Prev Res (Phila); 2009 Jun; 2(6):503-13. PubMed ID: 19491288 [No Abstract] [Full Text] [Related]
31. Chemopreventive alteration of the cell-cell adhesion in head and neck squamous cell cancer. Naim R; Chang RC; Schultz J; Hormann K Oncol Rep; 2006 Aug; 16(2):273-7. PubMed ID: 16820902 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties. Skopińska-Rózewska E; Piazza GA; Sommer E; Pamukcu R; Barcz E; Filewska M; Kupis W; Caban R; Rudziński P; Bogdan J; Mlekodaj S; Sikorska E Int J Tissue React; 1998; 20(3):85-9. PubMed ID: 9894180 [TBL] [Abstract][Full Text] [Related]
33. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813 [TBL] [Abstract][Full Text] [Related]
34. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. Kim KP; Whitehead C; Piazza G; Wargovich MJ Anticancer Res; 2004; 24(3a):1805-11. PubMed ID: 15274359 [TBL] [Abstract][Full Text] [Related]
36. Chemoprevention of colorectal cancer. Biasco G Tumori; 1997; 83(1 Suppl):S5-6. PubMed ID: 9154059 [No Abstract] [Full Text] [Related]
37. Modulation of apoptosis by cancer chemopreventive agents. D'Agostini F; Izzotti A; Balansky RM; Bennicelli C; De Flora S Mutat Res; 2005 Dec; 591(1-2):173-86. PubMed ID: 16137721 [TBL] [Abstract][Full Text] [Related]
38. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. Thompson HJ; Briggs S; Paranka NS; Piazza GA; Brendel K; Gross PH; Sperl GJ; Pamukcu R; Ahnen DJ J Natl Cancer Inst; 1995 Aug; 87(16):1259-60. PubMed ID: 7563174 [No Abstract] [Full Text] [Related]
40. Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC. Chang WC; Everley LC; Pfeiffer GR; Cooper HS; Barusevicius A; Clapper ML Ann N Y Acad Sci; 2005 Nov; 1059():41-55. PubMed ID: 16382042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]